0001697751-24-000003.txt : 20240426
0001697751-24-000003.hdr.sgml : 20240426
20240426130732
ACCESSION NUMBER: 0001697751-24-000003
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20240426
DATE AS OF CHANGE: 20240426
EFFECTIVENESS DATE: 20240426
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: AsclepiX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001697751
ORGANIZATION NAME:
IRS NUMBER: 832160334
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-511712
FILM NUMBER: 24881162
BUSINESS ADDRESS:
STREET 1: 301 WEST 29TH STREET, SUITE 2004
CITY: BALTIMORE
STATE: MD
ZIP: 21211
BUSINESS PHONE: 610-212-1217
MAIL ADDRESS:
STREET 1: 301 WEST 29TH STREET, SUITE 2004
CITY: BALTIMORE
STATE: MD
ZIP: 21211
FORMER COMPANY:
FORMER CONFORMED NAME: AsclepiX Therapeutics, LLC
DATE OF NAME CHANGE: 20170209
D
1
primary_doc.xml
X0708
D
LIVE
0001697751
AsclepiX Therapeutics, Inc.
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
610-212-1217
DELAWARE
AsclepiX Therapeutics, LLC
Corporation
true
2023
Robert
Dempsey
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Executive Officer
Steven
Altschuler
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Director
Ben
Askew
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Director
Josh
Barer
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Director
Chris
Garabedian
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Director
Jordan
Green
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Director
Sapna
Srivastava
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Director
Amir
Shojaei
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Executive Officer
Niranjan
Pandey
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Executive Officer
Jill
Tierney
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Executive Officer
Aleksander
Popel
5237 River Road
#334
Bethesda
MD
MARYLAND
20816
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2023-07-19
false
true
false
0
12544498
10044498
2500000
false
9
0
0
0
false
AsclepiX Therapeutics, Inc.
Robert Dempsey
Robert Dempsey
Chief Executive Officer
2024-04-26